Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Royalty Pharma
Biotech
Royalty's $275M financing deal for Denali drug awaiting FDA nod
While Denali awaits a delayed FDA decision on its Hunter syndrome drug, the biotech is already banking on the therapy’s commercial success.
James Waldron
Dec 4, 2025 10:20am
Royalty bestows Zenas with $300M for autoimmune approval push
Sep 2, 2025 11:07am
Royalty signs off $2B to bankroll Revolution's RAS cancer drug
Jun 24, 2025 9:00am
Biogen taps Royalty for $250M to fund phase 3 lupus program
Feb 12, 2025 8:10am
Investors say 'no bueno' to Cytokinetics' complex Royalty deal
May 23, 2024 10:36am
Karuna's new schizophrenia drug reaches FDA's desk
Sep 28, 2023 11:12am
